223 related articles for article (PubMed ID: 26861605)
1. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014.
Adra N; Althouse SK; Liu H; Brames MJ; Hanna NH; Einhorn LH; Albany C
Ann Oncol; 2016 May; 27(5):875-9. PubMed ID: 26861605
[TBL] [Abstract][Full Text] [Related]
2. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.
Oing C; Oechsle K; Necchi A; Loriot Y; De Giorgi U; Fléchon A; Daugaard G; Fedyanin M; Faré E; Bokemeyer C
Ann Oncol; 2017 Mar; 28(3):576-582. PubMed ID: 27993806
[TBL] [Abstract][Full Text] [Related]
3. A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral center.
Necchi A; Giannatempo P; Lo Vullo S; Farè E; Raggi D; Marongiu M; Scanagatta P; Duranti L; Giovannetti R; Girelli L; Nicolai N; Piva L; Biasoni D; Torelli T; Catanzaro M; Stagni S; Maffezzini M; Gianni AM; Mariani L; Pastorino U; Salvioni R
Clin Genitourin Cancer; 2015 Feb; 13(1):87-93.e1. PubMed ID: 25044148
[TBL] [Abstract][Full Text] [Related]
4. High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience.
Adra N; Abonour R; Althouse SK; Albany C; Hanna NH; Einhorn LH
J Clin Oncol; 2017 Apr; 35(10):1096-1102. PubMed ID: 27870561
[TBL] [Abstract][Full Text] [Related]
5. A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
Necchi A; Pond GR; Nicolai N; Giannatempo P; Raggi D; Adra N; Hanna NH; Salvioni R; Einhorn LH; Albany C
Clin Genitourin Cancer; 2017 Apr; 15(2):306-312.e3. PubMed ID: 27594554
[TBL] [Abstract][Full Text] [Related]
6. DNA damage measured in blood cells predicts overall and progression-free survival in germ cell tumour patients.
Sestakova Z; Kalavska K; Smolkova B; Miskovska V; Rejlekova K; Sycova-Mila Z; Palacka P; Obertova J; Holickova A; Hurbanova L; Jurkovicova D; Roska J; Goffa E; Svetlovska D; Chovanec M; Mardiak J; Mego M; Chovanec M
Mutat Res Genet Toxicol Environ Mutagen; 2020; 854-855():503200. PubMed ID: 32660824
[TBL] [Abstract][Full Text] [Related]
7. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors.
Kesler KA; Rieger KM; Hammoud ZT; Kruter LE; Perkins SM; Turrentine MW; Schneider BP; Einhorn LH; Brown JW
Ann Thorac Surg; 2008 Feb; 85(2):371-8. PubMed ID: 18222228
[TBL] [Abstract][Full Text] [Related]
8. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
[TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
10. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling.
Kollmannsberger C; Nichols C; Meisner C; Mayer F; Kanz L; Bokemeyer C
Ann Oncol; 2000 Sep; 11(9):1115-20. PubMed ID: 11061604
[TBL] [Abstract][Full Text] [Related]
11. Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy.
Shamash J; Mee M; Sarker SJ; Wilson P; Ansell W; Greenwood M; Berney D; Alifrangis C
BJU Int; 2020 Jun; 125(6):843-852. PubMed ID: 31688976
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
Necchi A; Farè E; Vullo SL; Giannatempo P; Raggi D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Verzoni E; Grassi P; Procopio G; Pizzocaro G; Mariani L; Salvioni R
Clin Genitourin Cancer; 2015 Aug; 13(4):385-391.e1. PubMed ID: 25726505
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients.
Gonzalez-Billalabeitia E; Castellano D; Sobrevilla N; Guma J; Hervas D; Luengo MI; Aparicio J; Sanchez-Muñoz A; Mellado B; Saenz A; Valverde C; Fernandez A; Margeli M; Duran I; Fernandez S; Sastre J; Ros S; Maroto P; Manneh R; Cerezuela P; Carmona-Bayonas A; Ayala de la Peña F; Luis Aguilar J; Rivera S; García Del Muro X; Germà-Lluch JR;
J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122896
[TBL] [Abstract][Full Text] [Related]
14. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis.
Hartmann JT; Einhorn L; Nichols CR; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Schmoll HJ; Kanz L; Bokemeyer C
J Clin Oncol; 2001 Mar; 19(6):1641-8. PubMed ID: 11250992
[TBL] [Abstract][Full Text] [Related]
15. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.
Raggi D; Mariani L; Giannatempo P; Lo Vullo S; Giardiello D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Calareso G; Magni M; Di Nicola M; Verzoni E; Grassi P; Procopio G; De Braud F; Pizzocaro G; Salvioni R; Necchi A
Urol Oncol; 2015 Jul; 33(7):332.e19-24. PubMed ID: 25985712
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
17. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
[TBL] [Abstract][Full Text] [Related]
19. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial germ cell tumor.
Takada A; Ii N; Hirayama M; Toyoda H; Matsubara T; Toyomasu Y; Kawamura T; Daimon T; Sakuma H; Nomoto Y
J Neurosurg Pediatr; 2018 Nov; 23(3):317-324. PubMed ID: 30497152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]